

(Pub. L. 111–11, title XIV, §14101, Mar. 30, 2009, 123 Stat. 1452.)

CODIFICATION

Section was enacted as part of the Christopher and Dana Reeve Paralysis Act, and also as part of the Omnibus Public Land Management Act of 2009, and not as part of the Public Health Service Act which comprises this chapter.

**§ 284p. Activities of the National Institutes of Health with respect to research with implications for enhancing daily function for persons with paralysis**

**(a) In general**

The Director, pursuant to the general authority of the Director, may make awards of grants to public or private entities to pay all or part of the costs of planning, establishing, improving, and providing basic operating support to multicenter networks of clinical sites that will collaborate to design clinical rehabilitation intervention protocols and measures of outcomes on one or more forms of paralysis that result from central nervous system trauma, disorders, or stroke, or any combination of such conditions.

**(b) Research**

A multicenter network of clinical sites funded through this section may—

(1) focus on areas of key scientific concern, including—

- (A) improving functional mobility;
- (B) promoting behavioral adaptation to functional losses, especially to prevent secondary complications;
- (C) assessing the efficacy and outcomes of medical rehabilitation therapies and practices and assisting technologies;
- (D) developing improved assistive technology to improve function and independence; and
- (E) understanding whole body system responses to physical impairments, disabilities, and societal and functional limitations; and

(2) replicate the findings of network members or other researchers for scientific and translation purposes.

**(c) Coordination of clinical trials networks; reports**

The Director may, as appropriate, provide for the coordination of information among networks funded through this section and ensure regular communication among members of the networks, and may require the periodic preparation of reports on the activities of the networks and submission of reports to the Director.

(Pub. L. 111–11, title XIV, §14201, Mar. 30, 2009, 123 Stat. 1453.)

CODIFICATION

Section was enacted as part of the Christopher and Dana Reeve Paralysis Act, and also as part of the Omnibus Public Land Management Act of 2009, and not as part of the Public Health Service Act which comprises this chapter.

DEFINITION OF “DIRECTOR”

“Director” as meaning the Director of the National Institutes of Health, see section 284o(a) of this title.

**§ 284q. Pain research**

**(a) Research initiatives**

**(1) In general**

The Director of NIH is encouraged to continue and expand, through the Pain Consortium, an aggressive program of basic and clinical research on the causes of and potential treatments for pain.

**(2) Annual recommendations**

Not less than annually, the Pain Consortium, in consultation with the Division of Program Coordination, Planning, and Strategic Initiatives, shall develop and submit to the Director of NIH recommendations on appropriate pain research initiatives that could be undertaken with funds reserved under section 282a(c)(1) of this title for the Common Fund or otherwise available for such initiatives.

**(3) Definition**

In this subsection, the term “Pain Consortium” means the Pain Consortium of the National Institutes of Health or a similar trans-National Institutes of Health coordinating entity designated by the Secretary for purposes of this subsection.

**(b) Interagency Pain Research Coordinating Committee**

**(1) Establishment**

The Secretary shall establish not later than 1 year after March 23, 2010, and as necessary maintain a committee, to be known as the Interagency Pain Research Coordinating Committee (in this section referred to as the “Committee”), to coordinate all efforts within the Department of Health and Human Services and other Federal agencies that relate to pain research.

**(2) Membership**

**(A) In general**

The Committee shall be composed of the following voting members:

- (i) Not more than 7 voting Federal representatives appoint<sup>1</sup> by the Secretary from agencies that conduct pain care research and treatment.
- (ii) 12 additional voting members appointed under subparagraph (B).

**(B) Additional members**

The Committee shall include additional voting members appointed by the Secretary as follows:

- (i) 6 non-Federal members shall be appointed from among scientists, physicians, and other health professionals.
- (ii) 6 members shall be appointed from members of the general public, who are representatives of leading research, advocacy, and service organizations for individuals with pain-related conditions.

**(C) Nonvoting members**

The Committee shall include such nonvoting members as the Secretary determines to be appropriate.

<sup>1</sup> So in original. Probably should be “appointed”.